Novartis to collaborate with Borisy's new biotech; AMRI inks pact with Genentech; Satori raises cash;

@FierceBiotech: Inspire shares tank after lead CF drug fails Ph3. Story | Follow @FierceBiotech

@JohnCFierce: New drug approvals are low. Favre says he will retire. Some things never change. Follow @JohnCFierce

> Alexis Borisy's new biotech company, Foundation Medicine, has inked a deal to collaborate with Novartis. Foundation will adapt its genome based tests for use with Novartis' medications. "This pilot collaboration with Novartis represents our first pharmaceutical partnership, and we are delighted to accomplish this important milestone with one of the world's leading cancer therapeutic companies," said Borisy. Story

> AMRI has forged a research and licensing pact with Genentech for a family of antibacterial compounds. Genentech will receive an exclusive license to develop and commercialize multiple potential products from AMRI's antibacterial program and AMRI will collaborate with Genentech in a research program with the objective of identifying novel antibacterial agents. AMRI release

> Cambridge, MA-based Satori Pharmaceuticals has raised $7 million, part of a $22 million round. Story

> Las Vegas-based CardioVascular BioTherapeutics released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds. Data indicates that "CVBT's FGF-1 biological drug appears to be delivering efficacy at a level significantly greater than has been seen in any other treatments, for patients suffering from chronic ischemic diabetic wounds." CVBT release

> BioMed Realty Trust of San Diego has paid close to $15 million for life sciences facilities in buildings in Durham and in Cary. Report

And Finally... The Wall Street Journal chronicles the work of Eisai researchers who found a lethal agent in nature that was recently approved to treat late-stage breast cancer. Story

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.